| Code | CSB-RA023986MB9HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to MV-088, targeting TNFSF11 (Tumor Necrosis Factor Superfamily Member 11), also known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand). TNFSF11 is a critical cytokine that regulates bone metabolism by promoting osteoclast differentiation, activation, and survival. This protein plays a central role in the RANK/RANKL/OPG signaling pathway, which maintains skeletal integrity and calcium homeostasis. Dysregulation of TNFSF11 expression is associated with various pathological conditions including osteoporosis, bone metastases, rheumatoid arthritis, and multiple myeloma-induced bone disease. Elevated RANKL levels contribute to excessive bone resorption and skeletal complications in these disorders.
MV-088 is a biosimilar drug of denosumab, designed to bind and block RANKL, strongly inhibiting the formation, activation and survival of osteoclasts, thereby reducing bone resorption, increasing bone density, and preventing bone-related events. It is currently in the preclinical or early clinical development stage. This biosimilar provides researchers with a valuable tool for studying TNFSF11-mediated signaling pathways, exploring therapeutic targets in metabolic bone diseases, and investigating the molecular mechanisms underlying osteoclast biology. It supports experimental models examining bone remodeling, cancer-induced bone destruction, and inflammatory conditions affecting skeletal health.
There are currently no reviews for this product.